Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:NLNK

NewLink Genetics - NLNK Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$5.24
▼
$5.53
50-Day Range
$0.89
▼
$14.10
52-Week Range
$0.82
▼
$3.60
Volume
10,864 shs
Average Volume
547,540 shs
Market Capitalization
$202.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NLNK stock logo

About NewLink Genetics (NASDAQ:NLNK) Stock

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Receive NLNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter.

NLNK Stock News Headlines

August 3, 2021 | markets.businessinsider.com
Here's what Wall Street expects from NewLink Genetics's earnings
March 7, 2021 | markets.businessinsider.com
What Wall Street expects from NewLink Genetics's earnings
December 23, 2020 | reuters.com
Lumos Pharma Inc
July 23, 2020 | www.bloomberg.com
NewLink Genetics’ Indoximod + PROVENGE® Results in Statistically Significant Improvement in Radiographic Progression-Free Su
July 14, 2020 | www.reuters.com
NewLink Genetics’ investors can sue over cancer-therapy statements - 2nd Circuit
June 6, 2020 | www.bloomberg.com
NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to
June 6, 2020 | www.bloomberg.com
NewLink Genetics Announces Review of Clinical Programs
May 29, 2020 | finance.yahoo.com
Edited Transcript of LUMO earnings conference call or presentation 28-May-20 8:30pm GMT
May 25, 2020 | in.reuters.com
NewLink Genetics Corp (NLNK.O)
May 13, 2020 | www.bloomberg.com
NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program
May 12, 2020 | www.bloomberg.com
NewLink Genetics Reports First Quarter 2018 Financial Results
March 30, 2020 | finance.yahoo.com
Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board
March 18, 2020 | seekingalpha.com
NewLink shareholders back Lumos merger
March 18, 2020 | finance.yahoo.com
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
March 9, 2020 | www.msn.com
52 Healthcare Stocks Moving In Monday's Pre-Market Session
February 28, 2020 | seekingalpha.com
NewLink Genetics EPS beats by $0.06, beats on revenue
February 28, 2020 | finance.yahoo.com
NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
February 18, 2020 | finance.yahoo.com
NewLink (NLNK) to Report Q4 Earnings: What's in the Cards?
December 24, 2019 | www.baystreet.ca
NewLink Hooks up with Ellipses
December 24, 2019 | www.msn.com
20 Stocks Moving in Tuesday's Pre-Market Session
December 24, 2019 | feeds.benzinga.com
The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
December 24, 2019 | www.benzinga.com
4 Stocks To Watch For December 24, 2019
December 23, 2019 | seekingalpha.com
NewLink +16% on NLG207 license agreement
December 20, 2019 | 247wallst.com
The First Ebola Vaccine Has Been Approved in the US
December 20, 2019 | seekingalpha.com
NewLink Genetics up 33% on FDA nod for Merck Ebola vaccine
See More Headlines

Receive NLNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter.

NLNK Company Calendar

Last Earnings
11/06/2019
Today
11/27/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NLNK
CUSIP
65151110
CIK
1126234
Web
www.newlinkgenetics.com
Phone
515-296-5555
Fax
N/A
Employees
55
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-42,990,000.00
Net Margins
-4,592.84%
Pretax Margin
N/A
Return on Equity
-41.50%
Return on Assets
-33.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.98
Quick Ratio
7.98

Sales & Book Value

Annual Sales
$940,000.00
Price / Sales
215.63
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.11 per share
Price / Book
2.57

Miscellaneous

Outstanding Shares
37,328,000
Free Float
N/A
Market Cap
$202.69 million
Optionable
Optionable
Beta
1.17

Key Executives

  • Dr. Charles J. Link Jr. (Age 60)
    Co-Founder, Chairman, CEO & Chief Scientific Officer
  • Mr. Nicholas N. Vahanian (Age 52)
    Co-Founder, Pres, Chief Medical Officer & Director
  • Dr. Eugene P. Kennedy M.D. (Age 50)
    FACS, Chief Medical Officer
  • Mr. Brian Wiley (Age 51)
    Chief Commercial Officer
  • Mr. Carl W. Langren (Age 64)
    CFO & Principal Accounting Officer

Key Competitors

View All Competitors













NLNK Stock - Frequently Asked Questions

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) issued its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, hitting the consensus estimate of ($0.27). The biotechnology company earned $0.25 million during the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative trailing twelve-month return on equity of 41.50%.

What other stocks do shareholders of NewLink Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Novavax (NVAX), SunPower (SPWR), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Cara Therapeutics (CARA) and Gilead Sciences (GILD).

What is NewLink Genetics' stock symbol?

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

What is NewLink Genetics' stock price today?

One share of NLNK stock can currently be purchased for approximately $5.43.

How much money does NewLink Genetics make?

NewLink Genetics (NASDAQ:NLNK) has a market capitalization of $202.69 million and generates $940,000.00 in revenue each year. The biotechnology company earns $-42,990,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis.

How can I contact NewLink Genetics?

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The official website for the company is www.newlinkgenetics.com. The biotechnology company can be reached via phone at 515-296-5555 or via email at investor@linkp.com.

This page (NASDAQ:NLNK) was last updated on 11/27/2022 by MarketBeat.com Staff